Respiratory Syncytial Virus (RSV) is a common virus that can cause serious lung infections, particularly in older adults and those with underlying health conditions. Because there is no treatment for RSV (which can cause severe coughing, phlegm, and shortness of breath for months after infection), vaccination is an important preventive measure. Vaccination can help prevent severe illness and hospitalization.
Abrysvo® (Pfizer’s RSV vaccine) was previously approved only for adults aged 60 and older and for pregnant women. Health Canada has now expanded its use to include adults aged 18–59 who are at increased risk of RSV-related lung disease. This includes individuals with chronic heart or lung disease (such as asthma or COPD), diabetes, weakened immunity, kidney or liver disease, certain neurological conditions, or class 3 obesity (BMI ≥40).
Arexvy® (GSK’s RSV vaccine) remains approved for adults 50–59 at risk and all adults 60 and older, though eligibility may expand in the future.
Both Abrysvo® and Arexvy® remain publicly funded only for those 75 years and older and those between 60-74 years old who are considered ‘high risk’ for RSV. Some of those individuals include those living in seniors’ residences and long-term care homes. However, many people will receive this vaccine through private insurance or may decide to pay out of pocket. Check with your pharmacist or primary care provider to see if you are eligible for public coverage.
With more adults now eligible, it’s a good time to ask your healthcare team whether RSV vaccination should be part of your protection plan!
Joyce Ayad is a pharmacist at Charlton Health, who believes in providing patient-focused care, supported by her previous experience working with specialty drugs, the pharmaceutical industry, and more.